# Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

> **NCT02378935** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 205 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** VOX
- **DRUG:** SOF/VEL
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02378935
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-17
- **Primary completion:** 2016-02-01
- **Final completion:** 2016-04-12
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2020-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378935, "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02378935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*